David M. Vail

12.9k total citations · 2 hit papers
177 papers, 8.2k citations indexed

About

David M. Vail is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Small Animals. According to data from OpenAlex, David M. Vail has authored 177 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Pulmonary and Respiratory Medicine, 60 papers in Genetics and 39 papers in Small Animals. Recurrent topics in David M. Vail's work include Veterinary Oncology Research (122 papers), Virus-based gene therapy research (58 papers) and Infectious Diseases and Mycology (34 papers). David M. Vail is often cited by papers focused on Veterinary Oncology Research (122 papers), Virus-based gene therapy research (58 papers) and Infectious Diseases and Mycology (34 papers). David M. Vail collaborates with scholars based in United States, Canada and United Kingdom. David M. Vail's co-authors include Douglas H. Thamm, E. Gregory MacEwen, Ruthanne Chun, Cheryl A. London, Ilene D. Kurzman, Laura D. Garrett, Lisa J. Forrest, Gregory K. Ogilvie, Michelle Turek and William M. Adams and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

David M. Vail

173 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document

2013 342 citations Douglas H. Thamm, David M. Vail et al. Veterinary and Comparative Oncology profile →
Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats

2021 177 citations Amy K. LeBlanc, Jenna H. Burton et al. Veterinary and Comparative Oncology profile →

Peers

Countries citing papers authored by David M. Vail

Since Specialization

Citations

This map shows the geographic impact of David M. Vail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Vail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Vail more than expected).

Fields of papers citing papers by David M. Vail

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Vail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Vail. The network helps show where David M. Vail may publish in the future.

Co-authorship network of co-authors of David M. Vail

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Vail. A scholar is included among the top collaborators of David M. Vail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Vail. David M. Vail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma 2024 ·Melanoma Research ·Mark R. Albertini, Cindy Zuleger, Erik A. Ranheim, (unknown), Paul M. Sondel, Zachary S. Morris, Jens C. Eickhoff, Michael A. Newton, Irene M. Ong, Rene Welch, (unknown), Ilene D. Kurzman, Michelle Turek, David M. Vail	3
2	Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs 2023 ·Veterinary Immunology and Immunopathology ·Jenna H. Burton, Stephen Albert Johnston, David M. Vail, Jens C. Eickhoff, Kathryn Sykes, (unknown), Luhui Shen, Ana Gervassi, Rodney L. Page, Jennifer L. Willcox, (unknown), (unknown), (unknown), Jessica C. Ralston, (unknown), Ilene D. Kurzman, (unknown), (unknown), (unknown), Douglas H. Thamm	5
3	Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs 2020 ·Journal of Veterinary Internal Medicine ·(unknown), (unknown), Karri A. Meleo, Gerald Post, Craig A. Clifford, (unknown), David M. Vail, Philip J. Bergman, Douglas H. Thamm	8
4	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms 2018 ·Veterinary and Comparative Oncology ·Michael Willmann, Emir Hadzijusufovic, Olivier Hermine, Mauro Dacasto, Laura Marconato, Karin Bauer, Barbara Peter, (unknown), Gregor Eisenwort, Erika Jensen‐Jarolim, Mathias Müller, Michel Arock, David M. Vail, Peter Valent	17
5	Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma 2017 ·Veterinary Medicine and Science ·Cindy Zuleger, (unknown), Erik A. Ranheim, Ilene D. Kurzman, Michael D. Macklin, Michael A. Newton, Jedd D. Wolchok, David M. Vail, Elof Eriksson, Mark R. Albertini	10
6	Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma 2017 ·Journal of Veterinary Internal Medicine ·Douglas H. Thamm, David M. Vail, Gerald Post, Timothy M. Fan, Brenda Phillips, Sandra M. Axiak‐Bechtel, (unknown), Mary K. Klein, (unknown)	18
7	Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma 2015 ·PLoS ONE ·Melissa Paoloni, Christina Mazcko, Kimberly A. Selting, Susan E. Lana, Lisa G. Barber, Jeffrey Phillips, Katherine A. Skorupski, David M. Vail, Heather Wilson‐Robles, Barbara J. Biller, Anne C. Avery, Matti Kiupel, Amy K. LeBlanc, (unknown), Beatrice Brunkhorst, Robert M. Tighe, Chand Khanna	40
8	Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose‐finding study 2011 ·Veterinary and Comparative Oncology ·Cecilia Robat, Cheryl A. London, (unknown), (unknown), (unknown), Kim A. Selting, Ilene D. Kurzman, David M. Vail	42
9	Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour‐bearing dogs (excluding mast cell tumours): a phase I dose‐finding study 2011 ·Veterinary and Comparative Oncology ·(unknown), (unknown), (unknown), David M. Vail	33
10	Biological activity of toceranib (Palladia) in canine anal gland anal SAC adenocarcinoma (AGASACA) 2011 ·Veterinary and Comparative Oncology ·(unknown), David M. Vail, Douglas H. Thamm, Jeffrey N. Bryan, Josep Carreras, (unknown), Conor J. McNeill, (unknown), S. Ettinger, (unknown), (unknown), (unknown), Karri A. Meleo, Pamela D. Jones, (unknown), Rance M. Gamblin, Cheryl A. London	1
11	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document 2009 ·Veterinary and Comparative Oncology ·David M. Vail, Gina Μ. Michels, C. Khanna, Kim A. Selting, Cheryl A. London, (unknown)	217
12	Cooperative Activity of Cytotoxic Chemotherapy with Antiangiogenic Thrombospondin-I Peptides, ABT-526 in Pet Dogs with Relapsed Lymphoma 2006 ·Clinical Cancer Research ·Anthony Rusk, (unknown), (unknown), David M. Vail, Joanne C. Graham, V. E. Valli, Jack Henkin, (unknown), Chand Khanna	20
13	Canine Digital Tumors: A Veterinary Cooperative Oncology Group Retrospective Study of 64 Dogs 2005 ·Journal of Veterinary Internal Medicine ·Carolyn J. Henry, William G. Brewer, Elizabeth M. Whitley, Jeff W. Tyler, Gregory K. Ogilvie, (unknown), Leslie E. Fox, Wallace B. Morrison, (unknown), David M. Vail, John Berg	43
14	Ocular Sparing Using Intensity Modulated Radiation Therapy (IMRT) in a Canine Model of Spontaneous Sinonasal Cancer: Proof–of–Principle of Conformal Avoidance 2005 ·Investigative Ophthalmology & Visual Science ·P. E. Miller, Michelle Turek, Lisa J. Forrest, T Mackie, H. Jaradat, David M. Vail, Minesh P. Mehta	1
15	Treating thyroid and parathyroid neoplasia in dogs and cats 2004 ·Veterinary medicine ·David L. Panciera, Otto I. Lanz, David M. Vail	1
16	Preclinical evaluation of a sterically stabilized liposome-encapsulated cisplatin in clinically normal cats 1998 ·American Journal of Veterinary Research ·Douglas H. Thamm, David M. Vail	6
17	Differential cell analysis and phenotypic subtyping of lymphocytes in bronchoalveolar lavage fluid from clinically normal dogs 1995 ·American Journal of Veterinary Research ·David M. Vail, Peter A. Mahler, Steve A. Soergel	28
18	Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs 1991 ·Journal of the American Veterinary Medical Association ·Gregory K. Ogilvie, David M. Vail, Mary K. Klein, Barbara E. Powers, (unknown)	20
19	Metabolic alterations in patients with cancer cachexia. 1990 ·Compendium on Continuing Education for The Practicing Veterinarian ·David M. Vail, Gregory K. Ogilvie, (unknown)	11
20	Perianal adenocarcinoma in the canine male: a retrospective study of 41 cases 1990 ·Journal of the American Animal Hospital Association ·David M. Vail, S. J. Withrow, Patrícia Schwarz, Barbara E. Powers	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact